Canada Markets closed
  • S&P/TSX

    20,590.98
    -30.42 (-0.15%)
     
  • S&P 500

    4,356.45
    -53.68 (-1.22%)
     
  • DOW

    34,297.73
    -66.77 (-0.19%)
     
  • CAD/USD

    0.7923
    +0.0004 (+0.0467%)
     
  • CRUDE OIL

    85.17
    -0.43 (-0.50%)
     
  • BTC-CAD

    46,596.52
    +425.07 (+0.92%)
     
  • CMC Crypto 200

    840.11
    +29.51 (+3.64%)
     
  • GOLD FUTURES

    1,849.30
    -3.20 (-0.17%)
     
  • RUSSELL 2000

    2,004.03
    +16.11 (+0.81%)
     
  • 10-Yr Bond

    1.7830
    +0.0360 (+2.06%)
     
  • NASDAQ futures

    14,119.50
    -21.25 (-0.15%)
     
  • VOLATILITY

    31.16
    +2.31 (+8.01%)
     
  • FTSE

    7,371.46
    -122.67 (-1.64%)
     
  • NIKKEI 225

    27,075.97
    -55.37 (-0.20%)
     
  • CAD/EUR

    0.7006
    +0.0004 (+0.06%)
     

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - (BMRN)

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BMRN

New York, New York--(Newsfile Corp. - December 1, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

Shareholders who purchased shares of BMRN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=21815&from=5

CLASS PERIOD : January 13, 2020 to September 3, 2021

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: December 22, 2021 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=21815&from=5

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BMRN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 22, 2021. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106102

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting